-       Report 
   - September 2025
    -  250 Pages 
    Global
   
   From       €4029EUR$4,490USD£3,536GBP 
                -       Report 
   - July 2023
    -  110 Pages 
    Global
   
   From       €4038EUR$4,500USD£3,544GBP 
                -       Report 
   - December 2022
    -  44 Pages 
    Global
   
   From       €1795EUR$2,000USD£1,575GBP 
                -       Report 
   - August 2023
    -  84 Pages 
    Global
   
   From       €3500EUR$4,178USD£3,179GBP 
                      Toxoplasmosis is an infectious disease caused by the parasite Toxoplasma gondii. It is a major cause of morbidity and mortality in immunocompromised individuals, such as those with HIV/AIDS, and can cause severe birth defects in pregnant women. Treatment of toxoplasmosis is typically done with a combination of drugs, including sulfonamides, pyrimethamine, and clindamycin.
The toxoplasmosis drug market is a subset of the larger infectious diseases drug market. It is composed of a variety of drugs    used to treat and prevent toxoplasmosis, including sulfonamides, pyrimethamine, and clindamycin. These drugs are used in combination to treat the infection, and are often prescribed in combination with other drugs to prevent the development of drug resistance.
Some companies in the toxoplasmosis drug market include GlaxoSmithKline, Merck, Pfizer, Sanofi, and Novartis. Show Less   Read more